Table 3.
Patients receiving the most commonly used systemic treatments in each line of therapy, overall and by ECOG PS
| First line | Overall | PS 0 | PS 1 | PS 2+ | |
|---|---|---|---|---|---|
| N = 220 | n = 35 (15.9%) | n = 173 (78.6%) | n = 9 (4.1%) | ||
| n (%) | Mean (SD) No. of cycles | n (%) | n (%) | n (%) | |
| Cisplatin + 5‐FU | 102 (46.4) | 5.7 (0.9) | 20 (57.1) | 78 (45.1) | 3 (33.3) |
| Cisplatin + cetuximab + 5‐FU | 36 (16.4) | 6.3 (1.1) | 5 (14.3) | 31 (17.9) | 0a |
| Carboplatin + 5‐FU | 26 (11.8) | 5.7 (0.8) | 3 (8.6) | 16 (9.3) | 5 (55.6) |
| Cisplatin + capecitabine | 10 (4.5)a | N/Ab | 3 (8.6) | 7 (4.1)a | 0a |
| Cisplatin + 5‐FU + paclitaxel | 2 (0.9)a | N/Aa | 0a | 1 (0.6)a | 1 (11.1) |
| Second line | Overall | PS 0 | PS 1 | PS 2+ | |
|---|---|---|---|---|---|
| N = 220 | n = 5 (2.3%) | n = 172 (78.2%) | n = 38 (17.3%) | ||
| n (%) | Mean (SD) No. of cycles | n (%) | n (%) | n (%) | |
| Docetaxel | 99 (45.0) | 5.3 (1.3) | 1 (20.0) | 84 (48.8) | 10 (26.3) |
| Paclitaxel | 28 (12.7) | 5.6 (2.1) | 2 (40.0) | 18 (10.5) | 8 (21.1) |
| Carboplatin + paclitaxel | 19 (8.6) | 5.8 (0.7) | 0a | 16 (9.3) | 3 (7.9)a |
| Cetuximab | 19 (8.6) | 6.0 (1.9) | 0a | 7 (4.1)a | 12 (31.6) |
| Carboplatin + gemcitabine | 2 (0.9)a | N/Aa | 1 (20.0) | 0a | 1 (2.6)a |
| Cetuximab + 5‐FU | 1 (0.5)a | N/Aa | 1 (20.0) | 0a | 0a |
| Third line | Overall | PS 0 | PS 1 | PS 2+ | |
|---|---|---|---|---|---|
| N = 220 | n = 1 (<1.0%) | n = 116 (52.7%) | n = 95 (43.2%) | ||
| n (%) | Mean (SD) No. of cycles | n (%) | n (%) | n (%) | |
| Docetaxel | 40 (18.2) | 4.1 (1.6) | 1 (100.0) | 29 (25.0) | 10 (10.5)a |
| Cetuximab | 43 (19.6) | 6.6 (2.5) | 0a | 27 (23.3) | 15 (15.8) |
| Methotrexate | 43 (19.6) | 4.2 (1.7) | 0a | 22 (19.0) | 21 (22.1) |
| Gemcitabine | 27 (12.3)a | N/Ab | 0a | 6 (5.2)a | 16 (16.8) |
5‐FU: 5‐fluorouracil; ECOG: Eastern Cooperative Oncology Group; N/A: not available; PS: performance status; SD: standard deviation.
PS was requested before each line of therapy but was not reported for all patients; therefore, the total number of patients by PS in each line of therapy is <220, and the sum varies among lines of therapy. For each line of therapy, the three most commonly used treatments, overall and by ECOG PS, are presented in bold. Where two or three regimens were reported with equal frequency within a stratum (line of therapy and PS), more than three treatments are presented in bold for that stratum.
This regimen was not one of the three most commonly used in this stratum.
Mean (SD) number of cycles are reported only for the top regimens overall.